What is it about?
Not all gene mutations found in a cancer are created equal. For example, some EGFR mutations respond to treatment, while others don't. Yet, clinical trials often list recruitment criteria as "EGFR mutant" and published trial results never mention the exact mutation. This is not best practice for precision oncology. The exact mutation, i.e. EGFR T790M, should be required in clinical trial recruitment postings and scientific publishers need to insist on this as well. A collective effort with standards and requirements will propel precision oncology and make best use of next-generation sequencing.
Featured Image
Why is it important?
We need to break down data silos and make best use of data generated from patient tumors. Oncology clinical trials will have better recruitment if specific gene mutations are listed in a standardized format in the eligibility section.
Perspectives
Read the Original
This page is a summary of: Clinical Trials in Precision Oncology, Clinical Chemistry, November 2015, AACC,
DOI: 10.1373/clinchem.2015.247437.
You can read the full text:
Resources
JAX-CKB
JAX-CKB is a powerful tool for interpreting complex genomic profiles, and represents a valuable resource for clinicians and translational and clinical researchers. JAX-CKB advances JAX’s mission to discover genomic solutions for disease and empower the global biomedical community in the shared quest to improve human health.
Overview of JAX-CKB
Learn about using JAX-CKB to identify relevant oncology gene mutations, targeted therapies, and clinical trials. Find out how JAX-CKB can help you!
Contributors
The following have contributed to this page